Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design.

Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J, Wren BW.

J Med Microbiol. 2012 Jul;61(Pt 7):919-26. doi: 10.1099/jmm.0.039438-0. Epub 2012 Apr 19. Review.

PMID:
22516134
2.

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, Williamson D, Atkins TP, Prior JL, Wren BW.

Open Biol. 2013 May 22;3(5):130002. doi: 10.1098/rsob.130002.

3.

Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.

Cuccui J, Wren B.

J Pharm Pharmacol. 2015 Mar;67(3):338-50. doi: 10.1111/jphp.12321. Epub 2014 Sep 22. Review.

4.

In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.

Kämpf MM, Braun M, Sirena D, Ihssen J, Thöny-Meyer L, Ren Q.

Microb Cell Fact. 2015 Jan 23;14:12. doi: 10.1186/s12934-015-0195-7.

5.

Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.

Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M.

Glycoconj J. 2013 Jul;30(5):511-22. doi: 10.1007/s10719-012-9451-9. Epub 2012 Oct 6.

PMID:
23053636
6.
7.

Plant glycans: friend or foe in vaccine development?

Bosch D, Schots A.

Expert Rev Vaccines. 2010 Aug;9(8):835-42. doi: 10.1586/erv.10.83. Review.

PMID:
20673008
8.

Functional analysis of the Campylobacter jejuni N-linked protein glycosylation pathway.

Linton D, Dorrell N, Hitchen PG, Amber S, Karlyshev AV, Morris HR, Dell A, Valvano MA, Aebi M, Wren BW.

Mol Microbiol. 2005 Mar;55(6):1695-703.

PMID:
15752194
9.

Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.

Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M.

Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21. Epub 2005 Feb 9.

10.

Production of glycoprotein vaccines in Escherichia coli.

Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L.

Microb Cell Fact. 2010 Aug 11;9:61. doi: 10.1186/1475-2859-9-61.

11.

Modification of the Campylobacter jejuni N-linked glycan by EptC protein-mediated addition of phosphoethanolamine.

Scott NE, Nothaft H, Edwards AV, Labbate M, Djordjevic SP, Larsen MR, Szymanski CM, Cordwell SJ.

J Biol Chem. 2012 Aug 24;287(35):29384-96. doi: 10.1074/jbc.M112.380212. Epub 2012 Jul 2.

12.

The design of a capsule polysaccharide conjugate vaccine against Campylobacter jejuni serotype HS15.

Bertolo L, Ewing CP, Maue A, Poly F, Guerry P, Monteiro MA.

Carbohydr Res. 2013 Jan 25;366:45-9. doi: 10.1016/j.carres.2012.11.017. Epub 2012 Dec 2.

PMID:
23261782
13.

Production of initial-stage eukaryotic N-glycan and its protein glycosylation in Escherichia coli.

Srichaisupakit A, Ohashi T, Misaki R, Fujiyama K.

J Biosci Bioeng. 2015 Apr;119(4):399-405. doi: 10.1016/j.jbiosc.2014.09.016. Epub 2014 Oct 16.

PMID:
25449758
14.

Structural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB.

Ihssen J, Kowarik M, Wiesli L, Reiss R, Wacker M, Thöny-Meyer L.

BMC Biotechnol. 2012 Sep 24;12:67. doi: 10.1186/1472-6750-12-67.

15.

N-Linked glycoengineering for human therapeutic proteins in bacteria.

Pandhal J, Wright PC.

Biotechnol Lett. 2010 Sep;32(9):1189-98. doi: 10.1007/s10529-010-0289-6. Epub 2010 May 7.

PMID:
20449632
16.

Spectroscopic studies of the structure and stability of glycoconjugate vaccines.

Jones C, Lemercinier X, Crane DT, Gee CK, Austin S.

Dev Biol (Basel). 2000;103:121-36. Review. No abstract available.

PMID:
11214231
17.

Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.

Garcia-Quintanilla F, Iwashkiw JA, Price NL, Stratilo C, Feldman MF.

Front Microbiol. 2014 Jul 29;5:381. doi: 10.3389/fmicb.2014.00381. eCollection 2014.

18.

Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis.

Iwashkiw JA, Fentabil MA, Faridmoayer A, Mills DC, Peppler M, Czibener C, Ciocchini AE, Comerci DJ, Ugalde JE, Feldman MF.

Microb Cell Fact. 2012 Jan 25;11:13. doi: 10.1186/1475-2859-11-13.

19.
20.

Glycoconjugate vaccines: future combinations.

Paradiso PR, Lindberg AA.

Dev Biol Stand. 1996;87:269-75. Review.

PMID:
8854027
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk